Case Studies on Opill and Naloxone: Key Takeaways from the Latest Switch Approvals and What They Mean for Future Industry Opportunities
Foley partner Kyle Faget, co-chair of the firm’s Health Care Practice Group, is speaking at the Advanced Legal, Regulatory and Compliance Forum on OTC Drugs in a panel titled “Case Studies on Opill and Naloxone: Key Takeaways from the Latest Switch Approvals and What They Mean for Future Industry Opportunities.”
The panelists will discuss how the U.S. Food & Drug Administration’s (FDA) recent efforts to enhance accessibility of over the counter (OTC) drug products have set the stage for a wave of approved switches in the industry – a development being warmly embraced by non-prescription drug companies. This panel will:
- Analyze the high-profile switches shaping the OTC industry landscape.
- Opill
- Naloxone
- Explore what FDA has considered in approving the latest switches and hurdles the industry may face in obtaining future switches; and
- Assess the significance of the Opill switch and its implications on new opportunities for RX-OTC switches, particularly in the area of women’s health.
For 10% off your registration, use code S10-826-826L24.S
